Earendil Labs signed a global license and development agreement with WuXi XDC to use WuXi’s payload‑linker and manufacturing platform for multiple antibody‑drug conjugate (ADC) programs, with total deal value of up to about $885 million including milestones and royalties. WuXi XDC will support CMC development via its WuXiTecan‑2 CRDMO capability. Earendil will lead product development, regulatory submissions and commercialization, leveraging WuXi’s integrated ADC technologies to accelerate pipeline translation. The partnership follows Earendil’s prior high‑value discovery deals and underscores continued investor and industrial appetite for next‑generation ADC modalities. The deal highlights industry trends toward platform collaborations that combine AI‑driven biologics design with large‑scale ADC manufacturing and commercially proven linker‑payload technology.